News
Price for weight-loss drug gets cut to $199
Digest more
4don MSN
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...
Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback